Login | English | Deutsch

 Research Information System University of Greifswald




Originalartikel | erschienen - EPub | peer reviewed

Toxin exposure and HLA alleles determine serum antibody binding to toxic shock syndrome toxin 1 (TSST-1) of .


Frontiers in Immunology 2023 / September ; 14: 1229562 -



http://www.ncbi.nlm.nih.gov/pubmed/37731490[PubMed]


Bibliometric indicators



Citations (WOS) = 1

DOI = 10.3389/fimmu.2023.1229562

PubMed-ID = 37731490




Abstract

Life-threatening toxic shock syndrome is often caused by the superantigen toxic shock syndrome toxin-1 (TSST-1) produced by . A well-known risk factor is the lack of neutralizing antibodies. To identify determinants of the anti-TSST-1 antibody response, we examined 976 participants of the German population-based epidemiological Study of Health in Pomerania (SHIP-TREND-0). We measured anti-TSST-1 antibody levels, analyzed the colonization with TSST-1-encoding strains, and performed a genome-wide association analysis of genetic risk factors. TSST-1-specific serum IgG levels varied over a range of 4.2 logs and were elevated by a factor of 12.3 upon nasal colonization with TSST-1-encoding . Moreover, the anti-TSST-1 antibody levels were strongly associated with HLA class II gene loci. HLA-DRB1*03:01 and HLA-DQB1*02:01 were positively, and HLA-DRB1*01:01 as well as HLA-DQB1*05:01 negatively associated with the anti-TSST-1 antibody levels. Thus, both toxin exposure and HLA alleles affect the human antibody response to TSST-1.

Published in

Frontiers in Immunology


Year 2023
Month/Hj September
Impact Factor (2023)
Volume 14
Issue
Pages 1229562 -
Open Access nein
Peer reviewed ja
Article type Originalartikel
Article state erschienen - EPub
DOI 10.3389/fimmu.2023.1229562
PubMed-ID 37731490

Common journal data

Short name: FRONT IMMUNOL
ISSN: 1664-3224
eISSN: 1664-3224
Country: SWITZERLAND
Language: English
Categories:
  • IMMUNOLOGY


Impact factor trend

Year Impact Factor
2015 5.695
2016 6.429
2017 5.511
2018 4.716
2019 5.085
2020 7.561
2021 8.786
2022 7.3

FAQs | Legal Notice | Privacy Statement